此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项针对18岁或以上胆道癌参与者比较Nanvuranlat与医生最佳选择以选择剂量方案(A部分)并研究总生存期(B部分)的研究 (Beacon-BTC)

2026年9月24日 更新者:J-Pharma Co., Ltd.

一项评估Nanvuranlat在既往接受过治疗的晚期胆道癌患者中的疗效和安全性的3期、多中心、随机、开放标签研究

This study is designed to 1) select a dose regimen for continued development and 2) evaluate nanvuranlat versus Physicians Best Choice (PBC) (FOLFOX, FOLFIRI, or Best Supportive Care (BSC)) in participants aged 18 years and over with BTC. Participants enrolling in Part A the trial will be randomly assigned to receive 1 of 3 nanvuranlat dose regimens or PBC. In Part B, participants will be randomly assigned to receive nanvuranlat or PBC. Participants will receive treatment every 2 weeks for as long as they do not experience safety issues, or their cancer gets worse, and the study doctor feels they should stop treatment. Health measurements including physical examinations, vital signs, ECGs, and safety laboratory tests will be performed to monitor safety, and tumor imaging will be performed to monitor cancer response to treatment. Other exploratory makers will be measured to better understand how nanvuranlat works.

研究概览

详细说明

This is a Phase 3, multicenter, randomized, open-label, 2-part study designed to select a dose regimen for continued development (Part A) and evaluate the efficacy and safety of nanvuranlat versus PBC (Part B) for the treatment of patients with advanced (locally advanced or metastatic) BTC who have previously received 1 prior standard therapy for advanced BTC plus appropriate therapies targeting druggable molecular mutations/aberrations. Randomization will be stratified by disease subtypes: IHC, EHC, and GBC.

Part A (Dose Regimen Selection) - Three nanvuranlat dose regimens will be evaluated in Part A. Cohorts 1 and 2 will receive 50 or 75 mg of nanvuranlat via a 90-minute infusion, once daily for 5 days, followed by 9 days treatment free (Nanvuranlat-5/9). Cohort 3 will receive 375 mg of nanvuranlat via a 46-hour infusion once every 14 days (Nanvuranlat-46). Participants will be randomized 1:1:1:1 to 4 cohorts. Each treatment cycle will be 14 days and study intervention will be administered beginning on Day 1 during each treatment cycle, except for those participants receiving BSC who will receive care at the discretion of the Investigator.

Part B (Efficacy Evaluation) - Participants will be randomized 1:1 to either nanvuranlat (dose regimen selected in Part A) or PBC (FOLFOX, FOLFIRI, or BSC). Each treatment cycle will be 14 days and study intervention will be administered beginning on Day 1 during each treatment cycle, except for those participants receiving BSC who will receive care at the discretion of the Investigator.

研究类型

介入性

注册 (估计的)

480

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • California
      • Duarte、California、美国、91010
        • 招聘中
        • City of Hope (Site 107)
      • Orange、California、美国、92868
        • 招聘中
        • University of California at Irvine (Site 101)
      • Santa Monica、California、美国、90404
        • 尚未招聘
        • UCLA Medical Center (Site 117)
    • Florida
      • Tampa、Florida、美国、33612
        • 招聘中
        • Moffitt Cancer Center Magnolia Campus (Site 123)
    • Illinois
      • Zion、Illinois、美国、60099
        • 招聘中
        • City of Hope - Chicago Cancer Center (Site 128)
    • Kentucky
      • Louisville、Kentucky、美国、40127
        • 招聘中
        • Norton Cancer Institute (Site 115)
    • Louisiana
      • New Orleans、Louisiana、美国、70121
        • 招聘中
        • Ochsner Medical Center (Site 120)
    • Michigan
      • Detroit、Michigan、美国、48201
        • 招聘中
        • Karmanos Cancer Center (Site 109)
    • Minnesota
      • Minneapolis、Minnesota、美国、55455
        • 招聘中
        • Masonic Cancer Center, University of Minnesota (Site 116)
    • Nevada
      • Las Vegas、Nevada、美国、89169
        • 招聘中
        • Comprehensive Cancer Centers of Nevada - Central Valley (Site 124)
    • New Jersey
      • New Brunswick、New Jersey、美国、08901
        • 招聘中
        • Rutgers Cancer Institute of New Jersey (Site 103)
    • New York
      • Buffalo、New York、美国、14263
        • 招聘中
        • Rosewell Park Comprehensive Cancer Center (Site 114)
      • New York、New York、美国、10065
        • 招聘中
        • Memorial Sloan Kettering Cancer Center (Site 108)
    • Ohio
      • Cleveland、Ohio、美国、44106
        • 招聘中
        • University Hospitals Cleveland Medical Center Seidman Cancer Center (Site 111)
      • Columbus、Ohio、美国、43219
        • 招聘中
        • James Cancer Hospital and Solove Research Institute (Site 119)
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73120
        • 招聘中
        • Mercy Clinic (Site 110)
    • Texas
      • Dallas、Texas、美国、75390
        • 招聘中
        • University of Texas Southwestern Medical Center (Site 104)
    • Washington
      • Seattle、Washington、美国、98109
        • 招聘中
        • Fred Hutchinson Cancer Center Clinic (Site 122)

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

- Individuals are eligible to be included in the study only if all of the following criteria apply:

  1. At least 18 years of age inclusive at the time of signing the informed consent.

  2. Provides informed written consent according to local laws or regulations.

  3. Able and willing to comply with scheduled visits, treatment plans, procedures, and laboratory tests, including peripheral blood and urine sampling during the study.

  4. Willing to participate in LAT1 testing and NAT2 and transporter genotyping. Note: For LAT1 testing, if the participant does not have archival tissue and a fresh biopsy is not in the best interest of the participant, they will still be eligible for the trial.

  5. Cancer must be metastatic, locally advanced and unresectable, or not amenable to treatment with local therapies that could offer a reasonable likelihood of clinical benefit.

  6. Histologic or cytologic diagnosis of BTC.

  7. Has BTC that is classified as either an IHC, EHC, or GBC based on surgical, clinical, or laparoscopic findings and/or radiological imaging (eg, CT, MRI).

  8. Has received 1 prior appropriate platinum (cisplatin, carboplatin, or oxaliplatin)-based therapy for advanced disease (locally advanced or metastatic) with or without a mAb targeting PD-1 or PD-L1.

    1. Disease progression during or within 6 months of neoadjuvant or adjuvant treatment with a platinum-containing regimen will count as having received 1 prior regimen.
    2. If a patient has a mutation/fusion of IDH1, FGFR2 or NTRK, or an amplified, mutated, or overexpressed form of HER2, or a recognized aberration in a validated "driver" of BTC, and was treated with an appropriate targeted agent, or the patient's tumor was determined to be MSI-H and an appropriate PD-1/PD-L1 mAb was administered, the targeted therapy or immunotherapy will NOT count as a separate line of treatment.
  9. ECOG PS of 0 or 1.

  10. Expected life expectancy of at least 90 days after the first day of treatment as per the site Investigator.

  11. At least 1 measurable lesion by RECIST v1.1 based on imaging (eg, CT, MRI) performed within 28 days prior to initiation of study intervention. Those who have received prior local therapy, including but not limited to embolization, chemoembolization, radiation therapy, and/or other appropriate ablative procedures to a measurable lesion that is within the treatment and shown ≥ 20% growth in size since posttreatment assessment.

  12. Resolution to ≤ Grade 1 by the NCI CTCAE v 5.0 (or higher) of all clinically significant toxic effects of prior chemotherapy or other treatments, except for alopecia and peripheral neuropathy (these must have resolved to ≤ Grade 2). If medical therapy is required for the treatment of a laboratory abnormality, the dose and laboratory value(s) should be stable.

  13. Adequate hematologic function:

    1. ANC ≥ 1.5 × 109/L. Myeloid growth factors must not have been administered within 7 days before the participant's first dose of study intervention.
    2. Hemoglobin ≥ 8.5 g/dL and no RBC transfusions during the 14 days before the participant's first dose of study intervention.
    3. Platelet count ≥ 100 × 109/L and no platelet transfusions during the 14 days before the participant's first dose of study intervention.
  14. Adequate baseline organ function, as demonstrated by the following:

    1. eGFR ≥ 50 mL/min as estimated by CKD-EPI 2021.
    2. Bilirubin ≤ 2 × ULN (local institution).
    3. AST and ALT ≤ 5 × ULN (local institution).
  15. Adequate coagulation function as defined by INR ≤ 1.5 OR a PT ≤ 1.5 × ULN AND an aPTT ≤ 1.5 × ULN if not receiving anticoagulation therapy. Note: Participants may receive subtherapeutic doses of warfarin while on study to maintain patency of venous devices but not with therapeutic doses of warfarin. Participants may be treated with low-molecular weight heparin.

  16. Women of childbearing potential must be willing to use a highly effective method of contraception throughout the study and study follow up or for at least 9 months after the last dose of study intervention. Note: A woman is of nonchildbearing potential if she meets 1 of the following criteria: a) postmenopausal with at least 12 months of spontaneous amenorrhea; b) has had a bilateral oophorectomy; or c) has had a hysterectomy. Highly effective methods of contraception include:

    • Abstinence from sexual activity.
    • Hormonal contraception (eg, injection, implant, pill, patch, or vaginal ring as available in each country) associated with inhibition of ovulation (both estrogen and progestogen and progestogen only) in use for at least 30 days before administration of study intervention.
    • Intrauterine device in use for at least 30 days before administration of study intervention.
    • Intrauterine hormone-releasing system in use for at least 30 days before administration of study intervention.
    • Bilateral tubal occlusion/ligation at least 6 months before administration of study intervention.
    • Partner who has been vasectomized at least 6 months before administration of study intervention.
  17. Males and their female partners must use a highly effective method of birth control if female partner(s) is of childbearing potential, and males must not donate sperm during the study and for 9 months after the last dose of study intervention.

Exclusion Criteria:

  • Individuals will be excluded from study participation if they meet any of the following criteria:

    1. Received systemic therapy or an investigational agent before washing out, as follows:

      1. < 2 weeks prior to Cycle 1 Day 1 for systemic non-immune-based therapy
      2. < 3 weeks prior to Cycle 1 Day 1 for immune-based therapy
      3. ≤ 5 half-lives or 3 weeks (whichever is longer) prior to Cycle 1 Day 1 for an investigational agent
    2. Received radiotherapy to metastatic sites within 2 weeks of Cycle 1 Day 1. Patients must have recovered from all radiation-related toxicities and not require corticosteroids. A 1 week washout is permitted for palliative radiation with a limited port ≤ 2 weeks of radiotherapy to non-CNS disease.

    3. Underwent hepatic radiation, chemoembolization, or radiofrequency ablation < 4 weeks prior to Cycle 1 Day 1.

    4. Underwent major surgery < 3 weeks before Screening and has not recovered adequately from the procedure and/or any complications from the surgery prior to starting study intervention.

    5. Known active CNS metastases and/or carcinomatous meningitis. Those with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of PD for at least 4 weeks by repeat imaging), clinically stable, and without requirement of corticosteroid treatment for at least 14 days prior to first dose of study intervention. For those with a history of CNS involvement, repeat imaging should be performed during study screening. However, CNS imaging is not required prior to study entry unless there is clinical suspicion of CNS involvement.

    6. Clinically significant cardiovascular disease (eg, uncontrolled or any New York Heart Association Class 3 or 4 heart failure, uncontrolled angina, history of myocardial infarction, unstable angina, or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).

    7. Resting QTcF > 470 msec at screening.

    8. An additional active malignancy that is progressing or has required active treatment within the past 3 years. Cases involving a past cancer history with substantial potential for recurrence must be discussed with the Medical Monitor before study entry. Patients with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ (including transitional cell carcinoma, cervical intraepithelial neoplasia, breast cancer, and melanoma in situ), organ-confined prostate cancer with no evidence of PD.

    9. Require strong inhibitors of P-gp, BCRP, OATP1B1, OATP1B3, OATP1A2, and OAT3 transporters unless they can be transferred to other medications within ≥ 5 half-lives of treatment.

    10. Require sensitive substrates of OATP1B1 and OATP1B3 unless they can be transferred to other medications within ≥ 5 half-lives of treatment.

    11. Known positive status for HIV, has not been treated with established appropriate antiretroviral therapy for at least 4 weeks, and has a hydrophobic interaction chromatography viral load < 400 copies/mL and a CD4+ T-cell (CD4+) counts ≥ 350 cells/µL prior to enrollment. No HIV testing is required unless mandated by local health authority.

    12. Active or chronic HBV and active (not cured) HCV. Participants who are HBV carriers without active disease (HBV DNA titer < 1000 copies/mL or 200 IU/mL) or cured HCV (negative HCV RNA test) with confirmed viral clearance that are not receiving ongoing treatment and without residual chronic liver disease may be enrolled.

    13. An uncontrolled intercurrent illness including, but not limited to medical illness; uncontrolled infection requiring therapy; psychiatric illness; alcohol or drug dependence; social situations or a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator or Medical Monitor.

    14. Requires therapeutic doses of warfarin (ie, requires monitoring). A washout period of 7 days before administration of a participant's first dose of study intervention is required for those in whom therapeutic doses of warfarin are discontinued. Note: Warfarin at a low daily dose to maintain patency for indwelling venous catheters is allowed. Low-molecular weight heparin and direct-acting oral anticoagulants, according to the inclusion requirements pertaining to coagulation test results, are allowed.

    15. Clinically significant edema or intracavitary fluid collections (eg, ascites, pleural effusion, pericardial effusions) resulting in moderate symptoms and/or requiring frequent drainage.

    16. Previously developed shock, anaphylaxis, or renal disorder due to SBECD.

    17. WOCBP who is pregnant, lactating, or discontinued lactation < 12 weeks prior to Screening, or who plans to become pregnant or initiate lactation during the study.

    18. Known reaction or contraindication to any component of study intervention (ie, oxaliplatin, leucovorin [including levoleucovorin], and 5-FU [FOLFOX] and irinotecan, leucovorin, and 5-FU [FOLFIRI]).

    19. Known DPD deficiency. Screening for DPD deficiency is not mandated but should be considered in subjects who have had severe toxicity due to fluoropyrimidine-based therapy in the past.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Nanvuranlat 50mg

Nanvuranlat 50mg administered via a 90-minute intravenous infusion once daily for 5 consecutive days, followed by 9 days off treatment

Nanvuranlat, IV administration

实验性的:Navuranlat 75mg

Nanvuranlat 75mg administered via a 90-minute intravenous infusion once daily for 5 consecutive days, followed by 9 days off treatment

Nanvuranlat, IV administration

实验性的:Navuranlat 375mg

Nanvuranlat 375mg administered via a 46-hour continuous intravenous infusion once every 14 days

Nanvuranlat, IV administration

其他:Physicians Best Choice (PBC)
  1. FOLFOX regimen (Leucovorin, 5-Flurouracil and Oxaliplatin) administered on Day 1 of each 14 day cycle, or
  2. FOLFIRI regimen (Leucovorin, 5-Flurouracil and Irinotecan) administered once during 14 day cycle, or
  3. Best Supportive Care (BSC) including symptomatic therapeutics, palliative radiation for pre-existing metastases and transfusion of blood products administered at discretion of Investigator.
  1. FOLFOX regimen (Leucovorin, 5-Flurouracil and Oxaliplatin) administered on Day 1 of each 14 day cycle, or
  2. FOLFIRI regimen (Leucovorin, 5-Flurouracil and Irinotecan) administered once during 14 day cycle, or
  3. Best Supportive Care (BSC) including symptomatic therapeutics, palliative radiation for pre-existing metastases and transfusion of blood products administered at discretion of Investigator.
其他名称:
  • FOLFOX方案(亚叶酸、5-氟尿嘧啶和奥沙利铂)
  • FOLFIRI 方案(亚叶酸、5-氟尿嘧啶和伊立替康)
  • 最佳支持治疗 (BSC)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Part A: Preliminary Overall Survival (OS)
大体时间:From date of first dose of study intervention until death [Approx. 24 months].

OS is defined as the time from the date of Cycle 1 Day 1 to the date of death from any cause.

From date of first dose of study intervention until death [Approx. 24 months].
Part B: Overall Survival
大体时间:From date of first dose of study intervention until death [Approx. 36 months]

OS is defined as the time from the date of Cycle 1 Day 1 to the date of death from any cause.

From date of first dose of study intervention until death [Approx. 36 months]

次要结果测量

结果测量
措施说明
大体时间
Part B: Progression Free Survival
大体时间:From first dose of study intervention until disease progression or death (which ever occurs first) [Approx. 36 months].

PFS is defined as the time from the date of Cycle 1 Day 1 to the date of objectively determined progression of disease per the Investigators using RECIST version 1.1 or death from any cause, whichever occurs first.

From first dose of study intervention until disease progression or death (which ever occurs first) [Approx. 36 months].
Part B: Objective Response Rate
大体时间:From first dose of study intervention until disease progression or death (which ever occurs first) [Approx. 36 months].

ORR, defined as the proportion of patients achieving a best response of CR or PR per the Investigators using RECIST version 1.1.

From first dose of study intervention until disease progression or death (which ever occurs first) [Approx. 36 months].
Part B: Incidence of treatment-emergent adverse events (TEAEs)
大体时间:From first dose of study intervention and up to 30 days after last dose of study intervention [Approx. 36 months].

Incidence of TEAEs, including serious adverse events (SAEs)

From first dose of study intervention and up to 30 days after last dose of study intervention [Approx. 36 months].
Part B: Relative Dose Intensity
大体时间:From first dose of study intervention and up to first 8 weeks of treatment [Approx. 36 months].

Relative dose intensity is defined as the ratio of completed infusions to the total planned infusions of the study drug during the first 8 weeks of treatment.

From first dose of study intervention and up to first 8 weeks of treatment [Approx. 36 months].
Part B: Dose Reductions, Interruptions and Discontinuations
大体时间:From first dose of study intervention through last dose of study drug intervention [Approx. 36 months].

Incidence of dose reductions, Interruptions and Discontinuations

From first dose of study intervention through last dose of study drug intervention [Approx. 36 months].
Part B: Electrocardiograms
大体时间:From first dose of study intervention through last dose of study drug intervention [Approx. 36 months].

Proportion of patients with treatment-emergent clinically significant ECG abnormalities

From first dose of study intervention through last dose of study drug intervention [Approx. 36 months].

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Ghassan Abou-Alfa, MD、Memorial Sloan Kettering Cancer Center
  • 研究主任:Eric K Rowinsky, MD、Uniphar Development, LLC

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月11日

初级完成 (估计的)

2027年10月1日

研究完成 (估计的)

2027年10月1日

研究注册日期

首次提交

2025年11月11日

首先提交符合 QC 标准的

2025年11月24日

首次发布 (实际的)

2025年12月5日

研究记录更新

最后更新发布 (实际的)

2026年9月29日

上次提交的符合 QC 标准的更新

2026年9月24日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

IPD 计划说明

A decision on the sharing of IPD will be made upon completion of Part A (Dose Selection) of the study.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅